AtriCure Stock News

AtriCure Inc. (NASDAQ:ATRC) – Investment analysts at Piper Sandler upped their FY2020 earnings per share estimates for AtriCure in a research report issued on Tuesday, July 28th. Piper Sandler analy

AtriCure Inc. (NASDAQ:ATRC) – Equities research analysts at SVB Leerink issued their Q3 2020 EPS estimates for shares of AtriCure in a research report issued to clients and investors on Wednesday, J

Six IPOs and one SPAC are scheduled to raise $4.6 billion in the week ahead, with Rocket Mortgage parent Rocket Companies slated to complete the year's largest US IPO to date.

AtriCure, Inc. (NASDAQ:ATRC) defied analyst predictions to release its second-quarter results, which were ahead of...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time-to-time in AtriCure's SEC

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX) Capricor Therapeutics Inc (NASDAQ: CAPR) Fulgent Genetics Inc...

AtriCure, Inc. (NASDAQ:ATRC) Q2 2020 Earnings Conference Call July 28, 2020 4:30 P.M.

Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 123.53% over the past year to ($0.38), which beat the

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...

Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from...

Acutus Medical has filed to raise $75 million in a U.S. IPO, although the final figure may differ.

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts forecast that AtriCure Inc. (NASDAQ:ATRC) will announce sales of $34.56 million for the current quarter, according to Zacks. Five analysts have provided estimates for AtriCure’s